Just as I predicted, the press releases in the financial world will start to surface now and continue on a planned basis until Tysabri is conditionally re-approved. It's not about MS patients' health...it's all about the $$$$.
Kam, who has a background as an entrepreneur and manager in the medical products industry, says two factors that should help Tysabri are that no patients taking just Tysabri came down with PML, and that existing drugs to fight multiple sclerosis don’t work for 25% of MS patients. For those 100,000 or so patients in the U.S., Kam says Tysabri can greatly improve their quality of life.
I wonder how Kam knows that PML isn't such a potential problem....not even the researchers have the answers to this as yet. And the CRABs don't work for about 66% of patients, not 25%!
“Wall Street is beginning to agree that Tysabri will return, but Merril Lynch and Citibank both recently reiterated their sell recommendations, both citing their belief that Tysabri will be hard to sell to physicians and MS patients until the risks of PML are better understood,” says Kam
Now that's interesting.... he states that the unknown risks of PML will cause a hard sell to physicians. But later in the press release he says that since the risk of getting PML are only .01%, ( supposed data from Biogen/Elan based on their 3000 patients) it's well worth it since the deaths from aspirin are .02% ( data from millions of users) Hmmm...I wonder what number of deaths and other infectious complications we may see from Tysabri when the number of users starts to skyrocket?
“One of the common side effects of competing drugs is constant flu-like symptoms. If you caught the flu this winter, you know how miserable it can be. Imagine how it would affect your life if you had the flu all the time. That is what life is like for many of these 300,000 MS patients. An important fact I noted from the clinical trial data and interviews with MS patients is that Tysabri does not seem to give MS patients these same flu-like symptoms.
I'm sure the competition won't be impressed with comments like this about their drugs. The interferon drug makers have virtually ignored this common side effect about their products for years as they have raked in billions of dollars selling them.
I have no qualms about the MS patient deciding whether he/she will use Tysabri. That's their right. But some of the rationalization that the money experts are going to spew out in the next few months will be hard to swallow!